Replimune : 2025 Investor Day Presentation (aafc61)

REPL

Published on 06/24/2025 at 10:08

June 24, 2025

© 2025 Replimune Group Inc.

10:00-10:10 Delivering Oncolytic Immunotherapy to Patients

Sushil Patel, PhD, CEO

12:00-12:15 RPx in Skin Cancer

Kostas Xynos, MD, Chief Medical Officer

10:10-10:30 Advanced Melanoma: Landscape & RP1 Opportunities

Nikhil Khushalani, MD, Moffit Cancer Center

12:10-12:30

Sherrif Ibrahim, MD, PhD, Rochester Dermatologic Surgery

10:30-10:50 Interventional Radiology in Oncology Treatment

Rahul Sheth, MD, MD Anderson Cancer Center

10:50-11:10 Poised for Commercial Success

Chris Sarchi, Chief Commercial Officer

11:15-Noon Fireside Chat and Q&A

Sherrif Ibrahim, MD, PhD, Rochester Dermatologic Surgery Nikhil Khushalani, MD, Moffit Cancer Center

Kim Margolin, MD, PhD, Saint John's Cancer Institute Bhavesh Shah, RPh, Boston Medical Center

Rahul Sheth, MD, MD Anderson Cancer Center

12:30-12:45 RPx: Following the Data

Kostas Xynos, Chief Medical Officer

Nina Aragam, SVP, Portfolio Strategy & Program Management

© 2025 Replimune Group Inc.

© 2025 Replimune Group Inc. 3

Sushil Patel, Ph.D.

CEO

Chris Sarchi

Chief Commercial Officer

Emily Hill

Chief Financial Officer

Kostas Xynos, MD, PhD, MBA

Chief Medical Officer

Nina Aragam

SVP, Portfolio Strategy & Program Management

© 2025 Replimune Group Inc.

© 2025 Replimune Group Inc. 4

Sherrif Ibrahim, MD, PhD

Dermatologist

Dermatologist, Mohs Surgeon and Owner, Rochester Dermatologic Surgery & Associate Professor, University of Rochester

Nikhil Khushalani, MD

Medical Oncologist

Vice Chair, Department of Cutaneous Oncology at Moffitt Cancer Center

Kim Margolin, MD

Medical Oncologist

Medical Director, Borstein Family Foundation Melanoma Program at Saint John's Cancer Institute

Bhavesh Shah, RPh

Pharmacist

Chief Pharmacy Officer, Hematology Oncology at Boston Medical Center

Rahul Sheth, MD

Interventional Radiologist

Associate Professor, Department of Interventional Radiology at MD Anderson Cancer Center

© 2025 Replimune Group Inc.

© 2025 Replimune Group Inc. 5

Disclaimer

Replimune Group Inc. published this content on June 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 24, 2025 at 14:07 UTC.